Jim Simons
RVNC

Jim Simons’s Revance Therapeutics, Inc. RVNC Stock Holding History

Jim Simons’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-459,300
Closed -$2.38M – 3985
2024
Q3 		$2.38M Sell
459,300
-112,700
-20% -$560K ﹤0.01% 1897
2024
Q2 		$1.47M Buy
572,000
+198,300
+53% +$677K ﹤0.01% 2082
2024
Q1 		$1.84M Buy
+373,700
New +$2.21M ﹤0.01% 2084
2023
Q4 		– Sell
-178,500
Closed -$2.05M – 4219
2023
Q3 		$2.05M Sell
178,500
-32,017
-15% -$616K ﹤0.01% 1843
2023
Q2 		$5.33M Buy
+210,517
New +$6.56M 0.01% 1399
2020
Q2 		– Sell
-472,700
Closed -$7M – 3832
2020
Q1 		$7M Sell
472,700
-204,773
-30% -$4.24M 0.01% 1374
2019
Q4 		$11M Sell
677,473
-198,900
-23% -$3.08M 0.01% 1385
2019
Q3 		$11.4M Sell
876,373
-454,600
-34% -$5.56M 0.01% 1306
2019
Q2 		$17.3M Buy
1,330,973
+428,900
+48% +$5.41M 0.02% 1052
2019
Q1 		$14.2M Buy
902,073
+330,200
+58% +$5.73M 0.01% 1169
2018
Q4 		$11.5M Buy
571,873
+395,419
+224% +$8.71M 0.01% 1216
2018
Q3 		$4.38M Sell
176,454
-58,746
-25% -$1.6M ﹤0.01% 1890
2018
Q2 		$6.46M Buy
235,200
+85,300
+57% +$2.56M 0.01% 1613
2018
Q1 		$4.62M Buy
149,900
+61,944
+70% +$1.99M 0.01% 1867
2017
Q4 		$3.14M Buy
87,956
+8,164
+10% +$234K ﹤0.01% 2086
2017
Q3 		$2.2M Sell
79,792
-30,581
-28% -$741K ﹤0.01% 2255
2017
Q2 		$2.91M Buy
+110,373
New +$2.46M ﹤0.01% 2048
2016
Q1 		– Sell
-215,900
Closed -$7.38M – 3562
2015
Q4 		$7.38M Buy
215,900
+128,400
+147% +$4.45M 0.02% 1191
2015
Q3 		$2.6M Sell
87,500
-41,000
-32% -$1.25M 0.01% 1830
2015
Q2 		$4.11M Buy
128,500
+63,091
+96% +$1.62M 0.01% 1569
2015
Q1 		$1.36M Buy
+65,409
New +$1.13M ﹤0.01% 2146

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Jim Simons's RVNC Position: Q4 2024 in Review

Jim Simons sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 459,300 shares — an estimated $2.38M sold.

Jim Simons first reported a position in RVNC in Q1 2015 and held it in 21 quarters. The position peaked at $17.3M in Q2 2019. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Jim Simons reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Jim Simons sold 459,300 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $2.38M.
  • Jim Simons first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 21 quarters.
  • Jim Simons's Revance Therapeutics, Inc. position peaked at $17.3M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.